Changes in prostate cancer survival among insured patients in relation to USPSTF screening recommendations
Abstract Background To investigate the effects of the U.S. Preventive Services Task Force’s (USPSTF) 2012 recommendation against prostate-specific antigen (PSA)-based screening for prostate cancer on survival disparities based on insurance status. Prior to the USPSTF’s 2012 screening recommendation,...
Ausführliche Beschreibung
Autor*in: |
Isaac E. Kim [verfasserIn] Daniel D. Kim [verfasserIn] Sinae Kim [verfasserIn] Shuangge Ma [verfasserIn] Thomas L. Jang [verfasserIn] Eric A. Singer [verfasserIn] Saum Ghodoussipour [verfasserIn] Isaac Yi Kim [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2022 |
---|
Schlagwörter: |
---|
Übergeordnetes Werk: |
In: BMC Urology - BMC, 2003, 22(2022), 1, Seite 11 |
---|---|
Übergeordnetes Werk: |
volume:22 ; year:2022 ; number:1 ; pages:11 |
Links: |
---|
DOI / URN: |
10.1186/s12894-022-01045-0 |
---|
Katalog-ID: |
DOAJ039107787 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ039107787 | ||
003 | DE-627 | ||
005 | 20230308025553.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230227s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1186/s12894-022-01045-0 |2 doi | |
035 | |a (DE-627)DOAJ039107787 | ||
035 | |a (DE-599)DOAJ56b5fe2d999a41a39991e88766b90466 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
050 | 0 | |a RC870-923 | |
100 | 0 | |a Isaac E. Kim |e verfasserin |4 aut | |
245 | 1 | 0 | |a Changes in prostate cancer survival among insured patients in relation to USPSTF screening recommendations |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Abstract Background To investigate the effects of the U.S. Preventive Services Task Force’s (USPSTF) 2012 recommendation against prostate-specific antigen (PSA)-based screening for prostate cancer on survival disparities based on insurance status. Prior to the USPSTF’s 2012 screening recommendation, previous studies found that insured patients with prostate cancer had better outcomes than uninsured patients. Methods Using the SEER 18 database, we examined prostate cancer-specific survival (PCSS) based on diagnostic time period and insurance status. Patients were designated as belonging to the pre-USPSTF era if diagnosed in 2010–2012 or post-USPSTF era if diagnosed in 2014–2016. PCSS was measured with the Kaplan–Meier method, while disparities were measured with the Cox proportional hazards model. Results During the pre-USPSTF era, uninsured patients experienced worse PCSS compared to insured patients (adjusted HR 1.256, 95% CI 1.037–1.520, p = 0.020). This survival disparity was no longer observed during the post-USPSTF era as a result of decreased PCSS among insured patients combined with unchanged PCSS among uninsured patients (adjusted HR 0.946, 95% CI 0.642–1.394, p = 0.780). Conclusions Although the underlying reasons are not clear, the USPSTF’s 2012 PSA screening recommendation may have hindered insured patients from being regularly screened for prostate cancer and selectively led to worse outcomes for insured patients without affecting the survival of uninsured patients. | ||
650 | 4 | |a Prostate cancer | |
650 | 4 | |a Insurance | |
650 | 4 | |a Survival disparity | |
650 | 4 | |a SEER | |
653 | 0 | |a Diseases of the genitourinary system. Urology | |
700 | 0 | |a Daniel D. Kim |e verfasserin |4 aut | |
700 | 0 | |a Sinae Kim |e verfasserin |4 aut | |
700 | 0 | |a Shuangge Ma |e verfasserin |4 aut | |
700 | 0 | |a Thomas L. Jang |e verfasserin |4 aut | |
700 | 0 | |a Eric A. Singer |e verfasserin |4 aut | |
700 | 0 | |a Saum Ghodoussipour |e verfasserin |4 aut | |
700 | 0 | |a Isaac Yi Kim |e verfasserin |4 aut | |
773 | 0 | 8 | |i In |t BMC Urology |d BMC, 2003 |g 22(2022), 1, Seite 11 |w (DE-627)335488811 |w (DE-600)2059857-9 |x 14712490 |7 nnns |
773 | 1 | 8 | |g volume:22 |g year:2022 |g number:1 |g pages:11 |
856 | 4 | 0 | |u https://doi.org/10.1186/s12894-022-01045-0 |z kostenfrei |
856 | 4 | 0 | |u https://doaj.org/article/56b5fe2d999a41a39991e88766b90466 |z kostenfrei |
856 | 4 | 0 | |u https://doi.org/10.1186/s12894-022-01045-0 |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/1471-2490 |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_DOAJ | ||
912 | |a GBV_ILN_11 | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_206 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_2003 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4367 | ||
912 | |a GBV_ILN_4700 | ||
951 | |a AR | ||
952 | |d 22 |j 2022 |e 1 |h 11 |
author_variant |
i e k iek d d k ddk s k sk s m sm t l j tlj e a s eas s g sg i y k iyk |
---|---|
matchkey_str |
article:14712490:2022----::hneipottcnesriaaognueptetirltotupt |
hierarchy_sort_str |
2022 |
callnumber-subject-code |
RC |
publishDate |
2022 |
allfields |
10.1186/s12894-022-01045-0 doi (DE-627)DOAJ039107787 (DE-599)DOAJ56b5fe2d999a41a39991e88766b90466 DE-627 ger DE-627 rakwb eng RC870-923 Isaac E. Kim verfasserin aut Changes in prostate cancer survival among insured patients in relation to USPSTF screening recommendations 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Background To investigate the effects of the U.S. Preventive Services Task Force’s (USPSTF) 2012 recommendation against prostate-specific antigen (PSA)-based screening for prostate cancer on survival disparities based on insurance status. Prior to the USPSTF’s 2012 screening recommendation, previous studies found that insured patients with prostate cancer had better outcomes than uninsured patients. Methods Using the SEER 18 database, we examined prostate cancer-specific survival (PCSS) based on diagnostic time period and insurance status. Patients were designated as belonging to the pre-USPSTF era if diagnosed in 2010–2012 or post-USPSTF era if diagnosed in 2014–2016. PCSS was measured with the Kaplan–Meier method, while disparities were measured with the Cox proportional hazards model. Results During the pre-USPSTF era, uninsured patients experienced worse PCSS compared to insured patients (adjusted HR 1.256, 95% CI 1.037–1.520, p = 0.020). This survival disparity was no longer observed during the post-USPSTF era as a result of decreased PCSS among insured patients combined with unchanged PCSS among uninsured patients (adjusted HR 0.946, 95% CI 0.642–1.394, p = 0.780). Conclusions Although the underlying reasons are not clear, the USPSTF’s 2012 PSA screening recommendation may have hindered insured patients from being regularly screened for prostate cancer and selectively led to worse outcomes for insured patients without affecting the survival of uninsured patients. Prostate cancer Insurance Survival disparity SEER Diseases of the genitourinary system. Urology Daniel D. Kim verfasserin aut Sinae Kim verfasserin aut Shuangge Ma verfasserin aut Thomas L. Jang verfasserin aut Eric A. Singer verfasserin aut Saum Ghodoussipour verfasserin aut Isaac Yi Kim verfasserin aut In BMC Urology BMC, 2003 22(2022), 1, Seite 11 (DE-627)335488811 (DE-600)2059857-9 14712490 nnns volume:22 year:2022 number:1 pages:11 https://doi.org/10.1186/s12894-022-01045-0 kostenfrei https://doaj.org/article/56b5fe2d999a41a39991e88766b90466 kostenfrei https://doi.org/10.1186/s12894-022-01045-0 kostenfrei https://doaj.org/toc/1471-2490 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 22 2022 1 11 |
spelling |
10.1186/s12894-022-01045-0 doi (DE-627)DOAJ039107787 (DE-599)DOAJ56b5fe2d999a41a39991e88766b90466 DE-627 ger DE-627 rakwb eng RC870-923 Isaac E. Kim verfasserin aut Changes in prostate cancer survival among insured patients in relation to USPSTF screening recommendations 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Background To investigate the effects of the U.S. Preventive Services Task Force’s (USPSTF) 2012 recommendation against prostate-specific antigen (PSA)-based screening for prostate cancer on survival disparities based on insurance status. Prior to the USPSTF’s 2012 screening recommendation, previous studies found that insured patients with prostate cancer had better outcomes than uninsured patients. Methods Using the SEER 18 database, we examined prostate cancer-specific survival (PCSS) based on diagnostic time period and insurance status. Patients were designated as belonging to the pre-USPSTF era if diagnosed in 2010–2012 or post-USPSTF era if diagnosed in 2014–2016. PCSS was measured with the Kaplan–Meier method, while disparities were measured with the Cox proportional hazards model. Results During the pre-USPSTF era, uninsured patients experienced worse PCSS compared to insured patients (adjusted HR 1.256, 95% CI 1.037–1.520, p = 0.020). This survival disparity was no longer observed during the post-USPSTF era as a result of decreased PCSS among insured patients combined with unchanged PCSS among uninsured patients (adjusted HR 0.946, 95% CI 0.642–1.394, p = 0.780). Conclusions Although the underlying reasons are not clear, the USPSTF’s 2012 PSA screening recommendation may have hindered insured patients from being regularly screened for prostate cancer and selectively led to worse outcomes for insured patients without affecting the survival of uninsured patients. Prostate cancer Insurance Survival disparity SEER Diseases of the genitourinary system. Urology Daniel D. Kim verfasserin aut Sinae Kim verfasserin aut Shuangge Ma verfasserin aut Thomas L. Jang verfasserin aut Eric A. Singer verfasserin aut Saum Ghodoussipour verfasserin aut Isaac Yi Kim verfasserin aut In BMC Urology BMC, 2003 22(2022), 1, Seite 11 (DE-627)335488811 (DE-600)2059857-9 14712490 nnns volume:22 year:2022 number:1 pages:11 https://doi.org/10.1186/s12894-022-01045-0 kostenfrei https://doaj.org/article/56b5fe2d999a41a39991e88766b90466 kostenfrei https://doi.org/10.1186/s12894-022-01045-0 kostenfrei https://doaj.org/toc/1471-2490 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 22 2022 1 11 |
allfields_unstemmed |
10.1186/s12894-022-01045-0 doi (DE-627)DOAJ039107787 (DE-599)DOAJ56b5fe2d999a41a39991e88766b90466 DE-627 ger DE-627 rakwb eng RC870-923 Isaac E. Kim verfasserin aut Changes in prostate cancer survival among insured patients in relation to USPSTF screening recommendations 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Background To investigate the effects of the U.S. Preventive Services Task Force’s (USPSTF) 2012 recommendation against prostate-specific antigen (PSA)-based screening for prostate cancer on survival disparities based on insurance status. Prior to the USPSTF’s 2012 screening recommendation, previous studies found that insured patients with prostate cancer had better outcomes than uninsured patients. Methods Using the SEER 18 database, we examined prostate cancer-specific survival (PCSS) based on diagnostic time period and insurance status. Patients were designated as belonging to the pre-USPSTF era if diagnosed in 2010–2012 or post-USPSTF era if diagnosed in 2014–2016. PCSS was measured with the Kaplan–Meier method, while disparities were measured with the Cox proportional hazards model. Results During the pre-USPSTF era, uninsured patients experienced worse PCSS compared to insured patients (adjusted HR 1.256, 95% CI 1.037–1.520, p = 0.020). This survival disparity was no longer observed during the post-USPSTF era as a result of decreased PCSS among insured patients combined with unchanged PCSS among uninsured patients (adjusted HR 0.946, 95% CI 0.642–1.394, p = 0.780). Conclusions Although the underlying reasons are not clear, the USPSTF’s 2012 PSA screening recommendation may have hindered insured patients from being regularly screened for prostate cancer and selectively led to worse outcomes for insured patients without affecting the survival of uninsured patients. Prostate cancer Insurance Survival disparity SEER Diseases of the genitourinary system. Urology Daniel D. Kim verfasserin aut Sinae Kim verfasserin aut Shuangge Ma verfasserin aut Thomas L. Jang verfasserin aut Eric A. Singer verfasserin aut Saum Ghodoussipour verfasserin aut Isaac Yi Kim verfasserin aut In BMC Urology BMC, 2003 22(2022), 1, Seite 11 (DE-627)335488811 (DE-600)2059857-9 14712490 nnns volume:22 year:2022 number:1 pages:11 https://doi.org/10.1186/s12894-022-01045-0 kostenfrei https://doaj.org/article/56b5fe2d999a41a39991e88766b90466 kostenfrei https://doi.org/10.1186/s12894-022-01045-0 kostenfrei https://doaj.org/toc/1471-2490 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 22 2022 1 11 |
allfieldsGer |
10.1186/s12894-022-01045-0 doi (DE-627)DOAJ039107787 (DE-599)DOAJ56b5fe2d999a41a39991e88766b90466 DE-627 ger DE-627 rakwb eng RC870-923 Isaac E. Kim verfasserin aut Changes in prostate cancer survival among insured patients in relation to USPSTF screening recommendations 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Background To investigate the effects of the U.S. Preventive Services Task Force’s (USPSTF) 2012 recommendation against prostate-specific antigen (PSA)-based screening for prostate cancer on survival disparities based on insurance status. Prior to the USPSTF’s 2012 screening recommendation, previous studies found that insured patients with prostate cancer had better outcomes than uninsured patients. Methods Using the SEER 18 database, we examined prostate cancer-specific survival (PCSS) based on diagnostic time period and insurance status. Patients were designated as belonging to the pre-USPSTF era if diagnosed in 2010–2012 or post-USPSTF era if diagnosed in 2014–2016. PCSS was measured with the Kaplan–Meier method, while disparities were measured with the Cox proportional hazards model. Results During the pre-USPSTF era, uninsured patients experienced worse PCSS compared to insured patients (adjusted HR 1.256, 95% CI 1.037–1.520, p = 0.020). This survival disparity was no longer observed during the post-USPSTF era as a result of decreased PCSS among insured patients combined with unchanged PCSS among uninsured patients (adjusted HR 0.946, 95% CI 0.642–1.394, p = 0.780). Conclusions Although the underlying reasons are not clear, the USPSTF’s 2012 PSA screening recommendation may have hindered insured patients from being regularly screened for prostate cancer and selectively led to worse outcomes for insured patients without affecting the survival of uninsured patients. Prostate cancer Insurance Survival disparity SEER Diseases of the genitourinary system. Urology Daniel D. Kim verfasserin aut Sinae Kim verfasserin aut Shuangge Ma verfasserin aut Thomas L. Jang verfasserin aut Eric A. Singer verfasserin aut Saum Ghodoussipour verfasserin aut Isaac Yi Kim verfasserin aut In BMC Urology BMC, 2003 22(2022), 1, Seite 11 (DE-627)335488811 (DE-600)2059857-9 14712490 nnns volume:22 year:2022 number:1 pages:11 https://doi.org/10.1186/s12894-022-01045-0 kostenfrei https://doaj.org/article/56b5fe2d999a41a39991e88766b90466 kostenfrei https://doi.org/10.1186/s12894-022-01045-0 kostenfrei https://doaj.org/toc/1471-2490 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 22 2022 1 11 |
allfieldsSound |
10.1186/s12894-022-01045-0 doi (DE-627)DOAJ039107787 (DE-599)DOAJ56b5fe2d999a41a39991e88766b90466 DE-627 ger DE-627 rakwb eng RC870-923 Isaac E. Kim verfasserin aut Changes in prostate cancer survival among insured patients in relation to USPSTF screening recommendations 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Background To investigate the effects of the U.S. Preventive Services Task Force’s (USPSTF) 2012 recommendation against prostate-specific antigen (PSA)-based screening for prostate cancer on survival disparities based on insurance status. Prior to the USPSTF’s 2012 screening recommendation, previous studies found that insured patients with prostate cancer had better outcomes than uninsured patients. Methods Using the SEER 18 database, we examined prostate cancer-specific survival (PCSS) based on diagnostic time period and insurance status. Patients were designated as belonging to the pre-USPSTF era if diagnosed in 2010–2012 or post-USPSTF era if diagnosed in 2014–2016. PCSS was measured with the Kaplan–Meier method, while disparities were measured with the Cox proportional hazards model. Results During the pre-USPSTF era, uninsured patients experienced worse PCSS compared to insured patients (adjusted HR 1.256, 95% CI 1.037–1.520, p = 0.020). This survival disparity was no longer observed during the post-USPSTF era as a result of decreased PCSS among insured patients combined with unchanged PCSS among uninsured patients (adjusted HR 0.946, 95% CI 0.642–1.394, p = 0.780). Conclusions Although the underlying reasons are not clear, the USPSTF’s 2012 PSA screening recommendation may have hindered insured patients from being regularly screened for prostate cancer and selectively led to worse outcomes for insured patients without affecting the survival of uninsured patients. Prostate cancer Insurance Survival disparity SEER Diseases of the genitourinary system. Urology Daniel D. Kim verfasserin aut Sinae Kim verfasserin aut Shuangge Ma verfasserin aut Thomas L. Jang verfasserin aut Eric A. Singer verfasserin aut Saum Ghodoussipour verfasserin aut Isaac Yi Kim verfasserin aut In BMC Urology BMC, 2003 22(2022), 1, Seite 11 (DE-627)335488811 (DE-600)2059857-9 14712490 nnns volume:22 year:2022 number:1 pages:11 https://doi.org/10.1186/s12894-022-01045-0 kostenfrei https://doaj.org/article/56b5fe2d999a41a39991e88766b90466 kostenfrei https://doi.org/10.1186/s12894-022-01045-0 kostenfrei https://doaj.org/toc/1471-2490 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 22 2022 1 11 |
language |
English |
source |
In BMC Urology 22(2022), 1, Seite 11 volume:22 year:2022 number:1 pages:11 |
sourceStr |
In BMC Urology 22(2022), 1, Seite 11 volume:22 year:2022 number:1 pages:11 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
Prostate cancer Insurance Survival disparity SEER Diseases of the genitourinary system. Urology |
isfreeaccess_bool |
true |
container_title |
BMC Urology |
authorswithroles_txt_mv |
Isaac E. Kim @@aut@@ Daniel D. Kim @@aut@@ Sinae Kim @@aut@@ Shuangge Ma @@aut@@ Thomas L. Jang @@aut@@ Eric A. Singer @@aut@@ Saum Ghodoussipour @@aut@@ Isaac Yi Kim @@aut@@ |
publishDateDaySort_date |
2022-01-01T00:00:00Z |
hierarchy_top_id |
335488811 |
id |
DOAJ039107787 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ039107787</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230308025553.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/s12894-022-01045-0</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ039107787</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ56b5fe2d999a41a39991e88766b90466</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC870-923</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Isaac E. Kim</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Changes in prostate cancer survival among insured patients in relation to USPSTF screening recommendations</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Background To investigate the effects of the U.S. Preventive Services Task Force’s (USPSTF) 2012 recommendation against prostate-specific antigen (PSA)-based screening for prostate cancer on survival disparities based on insurance status. Prior to the USPSTF’s 2012 screening recommendation, previous studies found that insured patients with prostate cancer had better outcomes than uninsured patients. Methods Using the SEER 18 database, we examined prostate cancer-specific survival (PCSS) based on diagnostic time period and insurance status. Patients were designated as belonging to the pre-USPSTF era if diagnosed in 2010–2012 or post-USPSTF era if diagnosed in 2014–2016. PCSS was measured with the Kaplan–Meier method, while disparities were measured with the Cox proportional hazards model. Results During the pre-USPSTF era, uninsured patients experienced worse PCSS compared to insured patients (adjusted HR 1.256, 95% CI 1.037–1.520, p = 0.020). This survival disparity was no longer observed during the post-USPSTF era as a result of decreased PCSS among insured patients combined with unchanged PCSS among uninsured patients (adjusted HR 0.946, 95% CI 0.642–1.394, p = 0.780). Conclusions Although the underlying reasons are not clear, the USPSTF’s 2012 PSA screening recommendation may have hindered insured patients from being regularly screened for prostate cancer and selectively led to worse outcomes for insured patients without affecting the survival of uninsured patients.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Prostate cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Insurance</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Survival disparity</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">SEER</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the genitourinary system. Urology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Daniel D. Kim</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sinae Kim</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Shuangge Ma</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Thomas L. Jang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Eric A. Singer</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Saum Ghodoussipour</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Isaac Yi Kim</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">BMC Urology</subfield><subfield code="d">BMC, 2003</subfield><subfield code="g">22(2022), 1, Seite 11</subfield><subfield code="w">(DE-627)335488811</subfield><subfield code="w">(DE-600)2059857-9</subfield><subfield code="x">14712490</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:22</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:11</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1186/s12894-022-01045-0</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/56b5fe2d999a41a39991e88766b90466</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1186/s12894-022-01045-0</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1471-2490</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">22</subfield><subfield code="j">2022</subfield><subfield code="e">1</subfield><subfield code="h">11</subfield></datafield></record></collection>
|
callnumber-first |
R - Medicine |
author |
Isaac E. Kim |
spellingShingle |
Isaac E. Kim misc RC870-923 misc Prostate cancer misc Insurance misc Survival disparity misc SEER misc Diseases of the genitourinary system. Urology Changes in prostate cancer survival among insured patients in relation to USPSTF screening recommendations |
authorStr |
Isaac E. Kim |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)335488811 |
format |
electronic Article |
delete_txt_mv |
keep |
author_role |
aut aut aut aut aut aut aut aut |
collection |
DOAJ |
remote_str |
true |
callnumber-label |
RC870-923 |
illustrated |
Not Illustrated |
issn |
14712490 |
topic_title |
RC870-923 Changes in prostate cancer survival among insured patients in relation to USPSTF screening recommendations Prostate cancer Insurance Survival disparity SEER |
topic |
misc RC870-923 misc Prostate cancer misc Insurance misc Survival disparity misc SEER misc Diseases of the genitourinary system. Urology |
topic_unstemmed |
misc RC870-923 misc Prostate cancer misc Insurance misc Survival disparity misc SEER misc Diseases of the genitourinary system. Urology |
topic_browse |
misc RC870-923 misc Prostate cancer misc Insurance misc Survival disparity misc SEER misc Diseases of the genitourinary system. Urology |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
BMC Urology |
hierarchy_parent_id |
335488811 |
hierarchy_top_title |
BMC Urology |
isfreeaccess_txt |
true |
familylinks_str_mv |
(DE-627)335488811 (DE-600)2059857-9 |
title |
Changes in prostate cancer survival among insured patients in relation to USPSTF screening recommendations |
ctrlnum |
(DE-627)DOAJ039107787 (DE-599)DOAJ56b5fe2d999a41a39991e88766b90466 |
title_full |
Changes in prostate cancer survival among insured patients in relation to USPSTF screening recommendations |
author_sort |
Isaac E. Kim |
journal |
BMC Urology |
journalStr |
BMC Urology |
callnumber-first-code |
R |
lang_code |
eng |
isOA_bool |
true |
recordtype |
marc |
publishDateSort |
2022 |
contenttype_str_mv |
txt |
container_start_page |
11 |
author_browse |
Isaac E. Kim Daniel D. Kim Sinae Kim Shuangge Ma Thomas L. Jang Eric A. Singer Saum Ghodoussipour Isaac Yi Kim |
container_volume |
22 |
class |
RC870-923 |
format_se |
Elektronische Aufsätze |
author-letter |
Isaac E. Kim |
doi_str_mv |
10.1186/s12894-022-01045-0 |
author2-role |
verfasserin |
title_sort |
changes in prostate cancer survival among insured patients in relation to uspstf screening recommendations |
callnumber |
RC870-923 |
title_auth |
Changes in prostate cancer survival among insured patients in relation to USPSTF screening recommendations |
abstract |
Abstract Background To investigate the effects of the U.S. Preventive Services Task Force’s (USPSTF) 2012 recommendation against prostate-specific antigen (PSA)-based screening for prostate cancer on survival disparities based on insurance status. Prior to the USPSTF’s 2012 screening recommendation, previous studies found that insured patients with prostate cancer had better outcomes than uninsured patients. Methods Using the SEER 18 database, we examined prostate cancer-specific survival (PCSS) based on diagnostic time period and insurance status. Patients were designated as belonging to the pre-USPSTF era if diagnosed in 2010–2012 or post-USPSTF era if diagnosed in 2014–2016. PCSS was measured with the Kaplan–Meier method, while disparities were measured with the Cox proportional hazards model. Results During the pre-USPSTF era, uninsured patients experienced worse PCSS compared to insured patients (adjusted HR 1.256, 95% CI 1.037–1.520, p = 0.020). This survival disparity was no longer observed during the post-USPSTF era as a result of decreased PCSS among insured patients combined with unchanged PCSS among uninsured patients (adjusted HR 0.946, 95% CI 0.642–1.394, p = 0.780). Conclusions Although the underlying reasons are not clear, the USPSTF’s 2012 PSA screening recommendation may have hindered insured patients from being regularly screened for prostate cancer and selectively led to worse outcomes for insured patients without affecting the survival of uninsured patients. |
abstractGer |
Abstract Background To investigate the effects of the U.S. Preventive Services Task Force’s (USPSTF) 2012 recommendation against prostate-specific antigen (PSA)-based screening for prostate cancer on survival disparities based on insurance status. Prior to the USPSTF’s 2012 screening recommendation, previous studies found that insured patients with prostate cancer had better outcomes than uninsured patients. Methods Using the SEER 18 database, we examined prostate cancer-specific survival (PCSS) based on diagnostic time period and insurance status. Patients were designated as belonging to the pre-USPSTF era if diagnosed in 2010–2012 or post-USPSTF era if diagnosed in 2014–2016. PCSS was measured with the Kaplan–Meier method, while disparities were measured with the Cox proportional hazards model. Results During the pre-USPSTF era, uninsured patients experienced worse PCSS compared to insured patients (adjusted HR 1.256, 95% CI 1.037–1.520, p = 0.020). This survival disparity was no longer observed during the post-USPSTF era as a result of decreased PCSS among insured patients combined with unchanged PCSS among uninsured patients (adjusted HR 0.946, 95% CI 0.642–1.394, p = 0.780). Conclusions Although the underlying reasons are not clear, the USPSTF’s 2012 PSA screening recommendation may have hindered insured patients from being regularly screened for prostate cancer and selectively led to worse outcomes for insured patients without affecting the survival of uninsured patients. |
abstract_unstemmed |
Abstract Background To investigate the effects of the U.S. Preventive Services Task Force’s (USPSTF) 2012 recommendation against prostate-specific antigen (PSA)-based screening for prostate cancer on survival disparities based on insurance status. Prior to the USPSTF’s 2012 screening recommendation, previous studies found that insured patients with prostate cancer had better outcomes than uninsured patients. Methods Using the SEER 18 database, we examined prostate cancer-specific survival (PCSS) based on diagnostic time period and insurance status. Patients were designated as belonging to the pre-USPSTF era if diagnosed in 2010–2012 or post-USPSTF era if diagnosed in 2014–2016. PCSS was measured with the Kaplan–Meier method, while disparities were measured with the Cox proportional hazards model. Results During the pre-USPSTF era, uninsured patients experienced worse PCSS compared to insured patients (adjusted HR 1.256, 95% CI 1.037–1.520, p = 0.020). This survival disparity was no longer observed during the post-USPSTF era as a result of decreased PCSS among insured patients combined with unchanged PCSS among uninsured patients (adjusted HR 0.946, 95% CI 0.642–1.394, p = 0.780). Conclusions Although the underlying reasons are not clear, the USPSTF’s 2012 PSA screening recommendation may have hindered insured patients from being regularly screened for prostate cancer and selectively led to worse outcomes for insured patients without affecting the survival of uninsured patients. |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
container_issue |
1 |
title_short |
Changes in prostate cancer survival among insured patients in relation to USPSTF screening recommendations |
url |
https://doi.org/10.1186/s12894-022-01045-0 https://doaj.org/article/56b5fe2d999a41a39991e88766b90466 https://doaj.org/toc/1471-2490 |
remote_bool |
true |
author2 |
Daniel D. Kim Sinae Kim Shuangge Ma Thomas L. Jang Eric A. Singer Saum Ghodoussipour Isaac Yi Kim |
author2Str |
Daniel D. Kim Sinae Kim Shuangge Ma Thomas L. Jang Eric A. Singer Saum Ghodoussipour Isaac Yi Kim |
ppnlink |
335488811 |
callnumber-subject |
RC - Internal Medicine |
mediatype_str_mv |
c |
isOA_txt |
true |
hochschulschrift_bool |
false |
doi_str |
10.1186/s12894-022-01045-0 |
callnumber-a |
RC870-923 |
up_date |
2024-07-03T21:38:49.260Z |
_version_ |
1803595524878630912 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ039107787</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230308025553.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/s12894-022-01045-0</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ039107787</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ56b5fe2d999a41a39991e88766b90466</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC870-923</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Isaac E. Kim</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Changes in prostate cancer survival among insured patients in relation to USPSTF screening recommendations</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Background To investigate the effects of the U.S. Preventive Services Task Force’s (USPSTF) 2012 recommendation against prostate-specific antigen (PSA)-based screening for prostate cancer on survival disparities based on insurance status. Prior to the USPSTF’s 2012 screening recommendation, previous studies found that insured patients with prostate cancer had better outcomes than uninsured patients. Methods Using the SEER 18 database, we examined prostate cancer-specific survival (PCSS) based on diagnostic time period and insurance status. Patients were designated as belonging to the pre-USPSTF era if diagnosed in 2010–2012 or post-USPSTF era if diagnosed in 2014–2016. PCSS was measured with the Kaplan–Meier method, while disparities were measured with the Cox proportional hazards model. Results During the pre-USPSTF era, uninsured patients experienced worse PCSS compared to insured patients (adjusted HR 1.256, 95% CI 1.037–1.520, p = 0.020). This survival disparity was no longer observed during the post-USPSTF era as a result of decreased PCSS among insured patients combined with unchanged PCSS among uninsured patients (adjusted HR 0.946, 95% CI 0.642–1.394, p = 0.780). Conclusions Although the underlying reasons are not clear, the USPSTF’s 2012 PSA screening recommendation may have hindered insured patients from being regularly screened for prostate cancer and selectively led to worse outcomes for insured patients without affecting the survival of uninsured patients.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Prostate cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Insurance</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Survival disparity</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">SEER</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the genitourinary system. Urology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Daniel D. Kim</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sinae Kim</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Shuangge Ma</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Thomas L. Jang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Eric A. Singer</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Saum Ghodoussipour</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Isaac Yi Kim</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">BMC Urology</subfield><subfield code="d">BMC, 2003</subfield><subfield code="g">22(2022), 1, Seite 11</subfield><subfield code="w">(DE-627)335488811</subfield><subfield code="w">(DE-600)2059857-9</subfield><subfield code="x">14712490</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:22</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:11</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1186/s12894-022-01045-0</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/56b5fe2d999a41a39991e88766b90466</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1186/s12894-022-01045-0</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1471-2490</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">22</subfield><subfield code="j">2022</subfield><subfield code="e">1</subfield><subfield code="h">11</subfield></datafield></record></collection>
|
score |
7.4014053 |